Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Share-based Compensation (2019 - 2025)

BridgeBio Pharma's Share-based Compensation history spans 7 years, with the latest figure at $34.6 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 14.98% year-over-year to $34.6 million; the TTM value through Dec 2025 reached $133.0 million, up 23.64%, while the annual FY2025 figure was $133.0 million, 38.86% up from the prior year.
  • Share-based Compensation for Q4 2025 was $34.6 million at BridgeBio Pharma, down from $35.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $35.3 million in Q3 2025 and bottomed at $16.1 million in Q3 2021.
  • The 5-year median for Share-based Compensation is $27.8 million (2022), against an average of $27.4 million.
  • The largest annual shift saw Share-based Compensation soared 241.38% in 2021 before it plummeted 30.87% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $22.5 million in 2021, then increased by 6.86% to $24.1 million in 2022, then increased by 28.14% to $30.8 million in 2023, then decreased by 2.27% to $30.1 million in 2024, then grew by 14.98% to $34.6 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Share-based Compensation are $34.6 million (Q4 2025), $35.3 million (Q3 2025), and $33.7 million (Q2 2025).